

Abstract 031: Tumor infiltrating lymphocyte (TIL) recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma

Joanna Pucilowska^a, Venkatesh Rajamanickam^a, Katherine Sanchez^a, Valerie Conrad^a, Nikki Moxon^a, Staci Mellinger^a, Alison Conlin^a, Maritza Martel^a, Kelly Perlewitz^a, Neil L. Berinstein^b, Monil Shah^b, David B. Page^a

^aProvidence Portland Medical Center, Portland, OR ^bBrooklyn ImmunoTherapeutics, New York, NY



Disclosures

Research Support:

Brooklyn ImmunoTherapeutics, Bristol-Myers Squibb, Merck, MedImmune

Advisory Boards:


Merck, Bristol-Myers Squibb, Nektar, Syndax, Nanostring, Puma, Myriad

Speakers Bureau and Speaking Engagements:

Genentech, Novartis


Introduction

- ~40,000 USA deaths from breast cancer recurrence annually¹
- TIL infiltration predicts freedom from recurrence and chemotherapy response²
- Anti-PD-1/L1 clinical activity in breast cancer, however activity is higher in PD-L1+ tumors³
- A locoregional immunotherapy approach may enhance response while minimizing toxicity



Hypothesis: Cytokine-based immunotherapy could be administered to regional lymphatics via subcutaneous injection, and may enhance TILs without added toxicity

Treatment and Clinical Trial Schematic



Legend: **Cy**=cyclophosphamide; **Sx**=surgery; **MDSC**=myeloid-derived suppressor cells

Components of therapy: Low-dose cyclophosphamide (Cy, 300mg/m²); peri-areolar IRX-2 SC injections (230 IU cytokine/d x 10); oral indomethacin (oral COX1/2 inhibitor)

Ref: ¹Egan et al., 2007; ²Whiteside et al., 2011; ³Wolf et al., 2018 ⁴Czystowska et al., 2009

Clinical Trial Objectives

Primary:

- To evaluate feasibility of pre-operative peri-lymphatic immunotherapy

Secondary:

- To evaluate for increases in stromal TILs¹

Exploratory:

- Pre/post-treatment PD-L1 expression
- Pre/post intratumoral immune cell phenotype/activation
- Peripheral blood treatment effects

Results: Subject Demographics

- Median age 55y (range 40-78)
- Majority of tumors are HR+HER2- (69%, n=11/16)
- Minority are HER2+ (25%, n=4/16)
- n=1 stage I TNBC tumor
- 50% grade I/II, 50% grade III
- 50% node-positive (n=8/16)

Clinical trial subjects

Patient ID	Age	Histology	Grade	Ki67%	Tumor size
IRXB-001	78	HR+Her2-	2	11%	1.9cm
IRXB-002	58	HR+Her2-	2	19%	2.4cm
IRXB-003	40	HR+Her2-	2	17%	3.0cm
IRXB-004	64	HR-Her2+	3	75%	4.2cm
IRXB-005	48	HR+Her2-	1	7%	1.7cm
IRXB-006	62	HR-Her2+	3	73%	2.7cm
IRXB-007	45	HR+Her2-	3	55%	3.7cm
IRXB-008	54	HR+Her2-	3	50%	2.1cm
IRXB-009	56	HR+Her2-	2	11%	0.7cm
IRXB-010	46	HR+Her2-	2	33%	1.8cm
IRXB-011	52	HR+Her2+	3	38%	1.5cm
IRXB-012	52	HR+Her2+	3	12%	2.1cm
IRXB-013	59	HR+Her2-	3	87%	2.2cm
IRXB-014	45	HR+Her2-	1	N/A	2.2cm
IRXB-015	61	HR+Her2-	2	30%	1.9cm
IRXB-016	66	TNBC	3	95%	1.0cm


Results: Feasibility

- No treatment-related grade III/IV toxicities;
- One treatment-unrelated transient grade III syncope in subject with prior history of vasovagal episodes
- Nausea and abdominal cramping associated with indomethacin (50%, 19%)
- Transient injection site erythema/bruising (50%, 44%)
- Minimal pain (19%), none requiring topical anesthesia

CTCAE 4.0 Toxicities occurring in >15% of subjects


Toxicity	Grade I/II, any attribution (%)	Grade I/II, Cy (%)	Grade I/II, Indo (%)	Grade I/II, IRX-2 (%)
Nausea	13 (81%)	3 (19%)	8 (50%)	
Bruising	8 (50%)			7 (44%)
Fatigue	9 (56%)	5 (31%)		
Injection site reaction	8 (50%)			8 (50%)
Abdominal cramping/bloating	4 (25%)		3 (19%)	
Increased ALT/AST/AlkP	4 (25%)			
Anemia	4 (25%)	1 (6%)	1 (6%)	
Headache	5 (31%)	1 (6%)		
Hypokalemia	4 (25%)			
Anorexia	3 (19%)			
Diarrhea	3 (19%)	1 (6%)	1 (6%)	
Flatulence	3 (19%)		2 (13%)	
Injection site pain	3 (19%)			3 (19%)
Vomiting	3 (19%)	2 (13%)	2 (13%)	

Results: TILs analysis



Results: Stromal TIL score


- 2015 San Antonio Working Group method¹
- sTIL increases in 11/16 subjects
- Mean +1.2-fold relative increase in sTIL score (p=.02, paired t-test)
- Mean +3.1% absolute increase in sTIL (p=.02, paired t-test)
- Intraobserver agreement among 2 blinded pathologists (Cohen's linear kappa=0.53)
- No obvious associations according to histologic type, grade, or Ki67



Results: PD-L1 expression

Nanostring mRNA expression


- Increases in PD-L1 mRNA observed in 75% of patients (n=12/16, p=.04, Wilcoxon matched-pairs rank test)
- Mean change mRNA expression +54% (p=.04, paired T-test)
- Increases observed across all histology types



Results: PD-L1 expression

PerkinElmer mIHC


- Increases in mean per-cell PD-L1 fluorescence in 80% of patients (n=12/15, p=.07, Wilcoxon matched-pairs rank test)
- Mean cell change in fluorescence +116% (p=NS)



Results: Nanostring immune profile


Relative increases in Nanostring mRNA signatures, including:

- immune checkpoint markers (OX40, PD-L1, IDO1, CTLA-4)
- leukocyte recruitment signature
- leukocyte markers
- cytotoxic T-cell signature




Results: Head and Neck SCC Cohort

- Similar increases in TIL score observed in HNSCC
- Mean 58% relative increase in score (range -57% to +452%, $p=.01$, paired T-test)
- No changes in PD-L1 mRNA, but higher baseline levels relative to ESBC cohort



Results: Peripheral Blood Effects (flow cytometry)

- Transient cyclophosphamide-associated T-regulatory cell depletion
- Transient depletion of effector T-cells, B-cells (not shown)



Conclusions

- Pre-operative, peri-lymphatic cytokine-based immunotherapy is feasible and well tolerated in early stage breast cancer
- Common toxicities included transient grade I/II IRX-related injection site reaction, indomethacin-associated nausea/GI upset
- Increase in sTILs and PD-L1 mRNA/protein

Caveats

- Heterogeneous tumor histology, primarily Luminal subtype (69%)
- No control arms to evaluate biopsy or cyclophosphamide effect
- Uncertain clinical relevance of observed effects

Future Directions

- Ongoing characterization of TILs via multispectral imaging (PerkinElmer)
- Phase II randomized trial to evaluate pCR rate following neoadjuvant pembrolizumab + chemotherapy +/- IRX-2 in stage II-III TNBC

Thank you!



EARLE A. CHILES
RESEARCH INSTITUTE

Joanna Pucilowska, PhD
Katherine Sanchez, MD
Valerie Conrad
William Redmond, PhD
Zhaoyu Sun, PhD
Yaping Wu, MD
Julie Cramer
Tracy Kelly
Kimberly Fox, JD
Amanda Seino
Nicole Fredrich



Monil Shah
Michael Lichtman
Lynn Sadowski-Mason
Neil Bernstein, MD
James Egan, PhD

T Cell Based Immunotherapy: A Deeper Dive III



Fairmont Kea Lani, Maui, HI
February 28 - March 4, 2019

This conference will bring together some of the most talented scientists involved with understanding T cell function and will promote discussions for possible therapeutic intervention in the setting of tumor immunology.

The three days will cover:

- Day 1** – Basic T cell biology and how it relates to therapeutics in a cancer-bearing host
- Day 2** – Preclinical data in human and mouse tumor models
- Day 3** – Immunotherapeutic intervention in cancer patients

This meeting will provide a unique “think tank” format that allows for lots of discussion to further dissect the intricacies of T cell function in tumor-bearing hosts. We also want to emphasize that while the meeting will be intense and thought provoking, the venue lends itself to having fun and relaxing. Hence, getting away from the rigors of your laboratories to the lush shores of Wailea will provide a creative atmosphere that will spawn new ideas in T cell biology.

Maui Meeting Speakers:

Basic T Cell Biology and Function:

- Stephen Hedrick, UC San Diego
- Federica Sallusto, Institute for Research in Biomedicine Università Della Svizzera Italiana
- Phil Greenberg, University of Washington
- Anthony Vella, UCONN Health
- Carl Ware, Sanford Burnham Prebys Medical Discovery Institute
- Andrew Weinberg, Providence Cancer Institute
- John Wherry, University of Pennsylvania

Preclinical Cancer Immunotherapy:

- James Allison, MD Anderson
- Robert Schreiber, Washington University School of Medicine in St. Louis
- Dario Vignali, University of Pittsburgh
- Randolph Noelle, Dartmouth
- Bernard Fox, Providence Cancer Institute
- Erika Pearce, Max Planck Institute of Immunobiology and Epigenetics
- Douglas Green, St. Jude's Children's Research Hospital
- Greg Delgoffe, University of Pittsburgh

Clinical Immunotherapy:

- Jedd Wolchok, Memorial Sloan Kettering Cancer Center
- Carl June, University of Pennsylvania
- Padmanee Sharma, MD Anderson
- Robert Ferris, University of Pittsburgh
- Brendan Curti, Providence Cancer Institute
- James Heath, Institute for Systems Biology
- Eric Tran, Providence Cancer Institute
- Kelly Paulson, Fred Hutchinson Cancer Research Center

Academics: \$845 — Industry: \$1145

www.agonox.com/maui/

Act NOW — Registration for this meeting is limited.

Register by November 15, 2018 to receive the \$100 Early Bird Registration Discount



UNIVERSITY OF HAWAII
CANCER CENTER



David Page, MD
Nicole Moxon, RN
Staci Mellinger, RN
Alison Conlin, MD
James Imatani, MD
Shaghayegh Aliabadi-Wahle, MD
Maritza Martel, MD
Carlo Bifulco, MD
Kristen Massimino, MD
Anupama Acheson, MD
Walter Urba, MD